Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Queensland Health
Baxter
Julphar
Dow
Moodys
Teva
Accenture
Deloitte

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OXYTOCIN 5 USP UNITS IN DEXTROSE 5%

« Back to Dashboard

Clinical Trials for Oxytocin 5 Usp Units In Dextrose 5%

Trial ID Title Status Sponsor Phase Summary
NCT00004363 Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed Northwestern University N/A OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed National Center for Research Resources (NCRR) N/A OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00107874 Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-Scheduled Cesarean Section Completed Basel Women’s University Hospital Phase 2 Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
NCT00114439 Lithium Cannabis Withdrawal Study Completed The University of New South Wales Phase 2 This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.
NCT00114439 Lithium Cannabis Withdrawal Study Completed Sydney South West Area Health Service Phase 2 This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.
NCT00116350 Misoprostol for the Treatment of Postpartum Hemorrhage Completed Family Care International N/A The purpose of this study is to test whether misoprostol is as effective as oxytocin for treating primary postpartum hemorrhage (PPH) with uterine atony as the suspected cause in two circumstances: 1) where women have received prophylactic uterotonics in the third stage of labor; and 2) where no prophylactic uterotonics have been given in the third stage of labor.
NCT00116350 Misoprostol for the Treatment of Postpartum Hemorrhage Completed Gynuity Health Projects N/A The purpose of this study is to test whether misoprostol is as effective as oxytocin for treating primary postpartum hemorrhage (PPH) with uterine atony as the suspected cause in two circumstances: 1) where women have received prophylactic uterotonics in the third stage of labor; and 2) where no prophylactic uterotonics have been given in the third stage of labor.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Oxytocin 5 Usp Units In Dextrose 5%

Condition Name

Condition Name for Oxytocin 5 Usp Units In Dextrose 5%
Intervention Trials
Postpartum Hemorrhage 59
Healthy 33
Schizophrenia 22
Pregnancy 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Oxytocin 5 Usp Units In Dextrose 5%
Intervention Trials
Hemorrhage 102
Postpartum Hemorrhage 99
Autistic Disorder 29
Disease 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Oxytocin 5 Usp Units In Dextrose 5%

Trials by Country

Trials by Country for Oxytocin 5 Usp Units In Dextrose 5%
Location Trials
United States 260
Canada 47
Egypt 42
China 24
Germany 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Oxytocin 5 Usp Units In Dextrose 5%
Location Trials
California 51
New York 25
Massachusetts 20
North Carolina 19
Maryland 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Oxytocin 5 Usp Units In Dextrose 5%

Clinical Trial Phase

Clinical Trial Phase for Oxytocin 5 Usp Units In Dextrose 5%
Clinical Trial Phase Trials
Phase 4 82
Phase 3 53
Phase 2/Phase 3 11
[disabled in preview] 190
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Oxytocin 5 Usp Units In Dextrose 5%
Clinical Trial Phase Trials
Completed 212
Recruiting 134
Not yet recruiting 71
[disabled in preview] 85
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Oxytocin 5 Usp Units In Dextrose 5%

Sponsor Name

Sponsor Name for Oxytocin 5 Usp Units In Dextrose 5%
Sponsor Trials
University of Electronic Science and Technology of China 21
Samuel Lunenfeld Research Institute, Mount Sinai Hospital 20
University of North Carolina, Chapel Hill 13
[disabled in preview] 46
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Oxytocin 5 Usp Units In Dextrose 5%
Sponsor Trials
Other 639
Industry 35
NIH 25
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Chubb
UBS
Federal Trade Commission
Express Scripts
Merck
McKinsey
Queensland Health
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.